Madrigal Pharmaceuticals Financial Statements
NASDAQ: MDGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 471.75 0.00%
Madrigal Pharmaceuticals revenue and earnings
In fiscal 2025, Madrigal Pharmaceuticals generated $958.4 million in revenue, up 432.1% from fiscal 2024, its 2nd consecutive year of revenue growth. Madrigal Pharmaceuticals reported a net loss of $288.3 million, compared with a loss of $465.9 million a year earlier. Operating margin was -31.3%.
Diluted earnings per share came in at -$10.15.
Summary generated from market data by MetaCap's automated system. Methodology
Madrigal Pharmaceuticals income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 958.40M | 180.13M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Revenue growth (YoY) | +432.05% | — | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | 6.23M | 0 | 0 | — | — | — | — | — | — |
| Gross Profit | — | 173.90M | 0 | 0 | — | — | — | — | — | — |
| Operating Expenses | 1.26B | 678.01M | 380.50M | 293.57M | 242.48M | 206.67M | 94.97M | 40.68M | 32.06M | 25.22M |
| Research & Development | 388.52M | 236.72M | 272.35M | 245.44M | 205.16M | 184.81M | 72.32M | 25.39M | 24.39M | 15.93M |
| Selling, General & Admin | 813.83M | 435.06M | 108.15M | 48.13M | — | — | — | — | — | — |
| Operating Income | -300.10M | -497.88M | -380.50M | -293.57M | -242.48M | -206.67M | -94.97M | -40.68M | -32.06M | -25.22M |
| Interest Expense | 22.31M | 14.67M | 12.71M | 3.96M | 0 | 0 | — | — | — | 1.21M |
| Other Income (Expense) | -463.00K | 0 | 0 | 0 | 273.00K | — | — | — | — | — |
| Pretax Income | -158.50M | -465.90M | -373.60M | — | — | — | — | — | — | — |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — |
| Net Income | -288.28M | -465.89M | -373.63M | -295.35M | -241.85M | -202.24M | -83.95M | -32.81M | -31.15M | -26.39M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -10.15 | -17.31 | -17.33 | -17.23 | -14.63 | -13.09 | -5.45 | -2.22 | -2.54 | -5.07 |
| EPS (Diluted) | -10.15 | -17.31 | -17.33 | -17.23 | -14.63 | -13.09 | -5.45 | -2.22 | -2.54 | -5.07 |
| Shares Outstanding (Basic) | 28.41M | 26.91M | 21.56M | 17.14M | 16.54M | 15.45M | 15.39M | 14.80M | 12.24M | 5.20M |
| Shares Outstanding (Diluted) | 28.41M | 26.91M | 21.56M | 17.14M | 16.54M | 15.45M | 15.39M | 14.80M | 12.24M | 5.20M |
| EBITDA | -298.59M | -496.78M | -379.97M | -293.10M | -242.08M | -206.20M | -94.86M | -40.59M | -31.98M | -25.22M |
| Gross Margin | — | 96.54% | — | — | — | — | — | — | — | — |
| Operating Margin | -31.31% | -276.39% | — | — | — | — | — | — | — | — |
| Net Margin | -30.08% | -258.64% | — | — | — | — | — | — | — | — |
This table shows 10 annual periods of Madrigal Pharmaceuticals's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow MDGL's reporting calendar. What is a income statement?